Search results
Results from the WOW.Com Content Network
Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [ 7 ] Pomalidomide was approved for medical use in the United States in February 2013, [ 10 ] and in the European Union in August 2013. [ 8 ]
The drug, renamed by that point as pomalidomide, advanced into phase 3 trials. Those trials also went very well and led to Celgene filing for U.S. and European regulatory approval in 2012. Present
As expected, the U.S. Food and Drug Administration granted approval on Feb. 8 for Celgene's Pomalyst in treating patients with multiple myeloma. Patients must have received at least two prior ...
Pomalidomide was submitted for FDA approval on April 26, 2012 [27] and on 21 June it was announced that the drug would get standard FDA review. A marketing authorization application was filed to EMA 21 June 2012, where a decision could come as soon as early 2013.
Pomalyst, a chemotherapy drug. Ibrance, a breast cancer drug. ... and as Medicare begins to cover the drugs for other FDA-approved ... The only way to avoid the tax is to pull the drug from the ...
Pomalidomide was approved in February 2013 by the FDA as a treatment for relapsed and refractory multiple myeloma. [97] It received a similar approval from the European Commission in August 2013, and is expected to be marketed in Europe under the brand name Imnovid. [98]
Pomalyst, treats multiple myeloma, AIDS-related Kaposi sarcoma. Ibrance, treats breast cancer ... Ozempic, which the US Food and Drug Administration has approved to treat diabetes, and Wegovy ...
In July 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with pomalidomide and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor. [36]